Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2024

This “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Understanding

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview

MAPK forms the backbone of four primary signal transduction cascades leading to the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1--2), JNK, p38 and ERK5. MAPK kinases 1 and 2, commonly known at MEK1--2, are referred to as MEK. Because of their importance in cell proliferation and signaling, MAPK pathways are being targeted for new drugs for oncology, inflammation and other conditions. Several inhibitors of MEK1--2 (MAPK kinases 1 and 2) are nearing, or are currently in, clinical trials for oncology.

MEK1 and 2 are downstream of genes frequently mutated in tumors (such as EGFR, RAS and RAF), and in preclinical models, MEK inhibitors have demonstrated potent antitumor activity. MEK inhibitors have shown objective responses when used as monotherapy, particularly in tumors with known BRAF-activating mutations.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors R&D. The therapies under development are focused on novel approaches for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors.

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Emerging Drugs Chapters

This segment of the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Emerging Drugs

• Selumetinib - AstraZeneca

Koselugo (selumetinib) is inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers.

Koselugo was granted US FDA Breakthrough Therapy Designation in April 2019, Rare Pediatric Disease Designation in December 2019, Orphan Drug Designation in February 2018, EU orphan designation in August 2018 and Swissmedic Orphan Drug Status in December 2018 for the treatment of paediatric patients with NF1 PN.

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors

There are approx. 10+ key companies which are developing the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors. The companies which have their Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Astrazeneca.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs.

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Report Insights

• Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs?
• How many Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• CStone Pharmaceuticals
• AUM Biosciences
• Novartis
• Array BioPharma
• Chongqing Fochon Pharmaceutical

Key Products

• Selumetinib
• CS 3006
• AUM 001
• Trametinib
• Binimetinib
• FCN 159